Zacks Research Issues Positive Estimate for Sanofi Earnings

Sanofi (NASDAQ:SNY) – Investment analysts at Zacks Research raised their FY2024 EPS estimates for Sanofi in a report released on Wednesday, November 13th. Zacks Research analyst K. Shah now expects that the company will earn $4.31 per share for the year, up from their prior estimate of $4.12. The consensus estimate for Sanofi’s current full-year earnings is $4.29 per share. Zacks Research also issued estimates for Sanofi’s Q4 2024 earnings at $0.84 EPS, Q1 2026 earnings at $1.17 EPS and Q2 2026 earnings at $1.16 EPS.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same period last year, the company posted $2.55 EPS. The business’s revenue was up 12.3% on a year-over-year basis.

SNY has been the subject of several other research reports. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, Argus raised their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Sanofi presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Performance

Shares of NASDAQ:SNY opened at $48.51 on Monday. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The stock has a market capitalization of $123.11 billion, a P/E ratio of 24.75, a PEG ratio of 1.22 and a beta of 0.61. The firm has a fifty day simple moving average of $54.45 and a two-hundred day simple moving average of $52.22. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Institutional Investors Weigh In On Sanofi

Several large investors have recently modified their holdings of the business. POM Investment Strategies LLC purchased a new position in shares of Sanofi in the 2nd quarter worth approximately $25,000. Northwest Investment Counselors LLC purchased a new position in shares of Sanofi in the 3rd quarter worth approximately $29,000. Concord Wealth Partners grew its position in shares of Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after buying an additional 363 shares during the last quarter. Arrow Financial Corp purchased a new position in shares of Sanofi in the 2nd quarter worth approximately $35,000. Finally, Fortitude Family Office LLC grew its position in shares of Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after buying an additional 659 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.